FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation
Open Access
- 24 February 2026
- journal article
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (6) , 1043-1054
Abstract
Fibroblast activation protein (FAP), a serine protease overexpressed in cancer-associated fibroblasts of >90% epithelial malignancies, has emerged as a highly promising pan-cancer target for theranostic radiopharmaceuticals. However, the rapid clearance of monomeric FAP inhibitors (FAPIs) limits their therapeutic efficacy despite excellent diagnostic performance. Multimerization strategies-particularly dimeric and heterodimeric constructs-have been developed to overcome this limitation through enhanced binding avidity and prolonged tumor retention. This review provides a comprehensive analysis of recent advances in FAPI-based multimers, focusing on their molecular design, chemical synthesis, preclinical evaluation, and early clinical applications. We examine the role of linker chemistry (length, flexibility, cleavability) and chelator selection in optimizing pharmacokinetics and tumor-to-background contrast. Key examples include homodimers (e.g., DOTA-2P(FAPI)2, BiOncoFAP) that leverage the polyvalency effect, and heterodimers (e.g., FAPI-RGD, PSFA-01) that enable dual-targeting of FAP and complementary receptors such as integrin αvβ3 or PSMA. These probes show superior tumor uptake and retention in preclinical models and have demonstrated enhanced diagnostic sensitivity and therapeutic potential in clinical trials across multiple cancer types. Beyond oncology, emerging applications in fibrotic and inflammatory diseases-such as rheumatoid arthritis and interstitial lung disease-highlight the versatile utility of FAPI multimers. While challenges including renal uptake, synthetic complexity, and cost remain, ongoing innovations in chemical design and combination therapies position these agents as transformative tools in precision theranostics, bridging high-contrast imaging with effective radioligand therapy for personalized patient management.Keywords
Funding Information
- Wuxi Medical Center (WMCG202531)
- Wuxi health commission (M202507)
This publication has 48 references indexed in Scilit:
- Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013European Journal of Nuclear Medicine and Molecular Imaging, 2024
- Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Hetero-bivalent agents targeting FAP and PSMAEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retentionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapyClinical & Translational Immunology, 2020
- Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapyProteomics – Clinical Applications, 2014